nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,

Page 1 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=1' data-page='1' class='cut-thumb lazyload' alt='Page 1: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/1.jpg' width='140' height='200' /> 1.

Page 2 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=2' data-page='2' class='cut-thumb lazyload' alt='Page 2: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/2.jpg' width='140' height='200' /> 2.

Page 3 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=3' data-page='3' class='cut-thumb lazyload' alt='Page 3: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/3.jpg' width='140' height='200' /> 3.

Page 4 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=4' data-page='4' class='cut-thumb lazyload' alt='Page 4: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/4.jpg' width='140' height='200' /> 4.

Page 5 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=5' data-page='5' class='cut-thumb lazyload' alt='Page 5: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/5.jpg' width='140' height='200' /> 5.

Page 6 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=6' data-page='6' class='cut-thumb lazyload' alt='Page 6: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/6.jpg' width='140' height='200' /> 6.

Page 7 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=7' data-page='7' class='cut-thumb lazyload' alt='Page 7: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/7.jpg' width='140' height='200' /> 7.

Page 8 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=8' data-page='8' class='cut-thumb lazyload' alt='Page 8: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/8.jpg' width='140' height='200' /> 8.

Page 9 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=9' data-page='9' class='cut-thumb lazyload' alt='Page 9: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/9.jpg' width='140' height='200' /> 9.

Page 10 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=10' data-page='10' class='cut-thumb lazyload' alt='Page 10: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/10.jpg' width='140' height='200' /> 10.

Page 11 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=11' data-page='11' class='cut-thumb lazyload' alt='Page 11: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/11.jpg' width='140' height='200' /> 11.

Page 12 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=12' data-page='12' class='cut-thumb lazyload' alt='Page 12: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/12.jpg' width='140' height='200' /> 12.

Page 13 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=13' data-page='13' class='cut-thumb lazyload' alt='Page 13: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/13.jpg' width='140' height='200' /> 13.

Page 14 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=14' data-page='14' class='cut-thumb lazyload' alt='Page 14: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/14.jpg' width='140' height='200' /> 14.

Page 15 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=15' data-page='15' class='cut-thumb lazyload' alt='Page 15: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/15.jpg' width='140' height='200' /> 15.

Page 16 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=16' data-page='16' class='cut-thumb lazyload' alt='Page 16: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/16.jpg' width='140' height='200' /> 16.

Page 17 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=17' data-page='17' class='cut-thumb lazyload' alt='Page 17: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/17.jpg' width='140' height='200' /> 17.

Page 18 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=18' data-page='18' class='cut-thumb lazyload' alt='Page 18: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/18.jpg' width='140' height='200' /> 18.

Page 19 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=19' data-page='19' class='cut-thumb lazyload' alt='Page 19: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/19.jpg' width='140' height='200' /> 19.

Page 20 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=20' data-page='20' class='cut-thumb lazyload' alt='Page 20: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/20.jpg' width='140' height='200' /> 20.

Page 21 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=21' data-page='21' class='cut-thumb lazyload' alt='Page 21: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/21.jpg' width='140' height='200' /> 21.

Page 22 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=22' data-page='22' class='cut-thumb lazyload' alt='Page 22: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/22.jpg' width='140' height='200' /> 22.

Page 23 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=23' data-page='23' class='cut-thumb lazyload' alt='Page 23: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/23.jpg' width='140' height='200' /> 23.

Page 24 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=24' data-page='24' class='cut-thumb lazyload' alt='Page 24: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/24.jpg' width='140' height='200' /> 24.

Page 25 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=25' data-page='25' class='cut-thumb lazyload' alt='Page 25: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/25.jpg' width='140' height='200' /> 25.

Page 26 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=26' data-page='26' class='cut-thumb lazyload' alt='Page 26: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/26.jpg' width='140' height='200' /> 26.

Page 27 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=27' data-page='27' class='cut-thumb lazyload' alt='Page 27: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/27.jpg' width='140' height='200' /> 27.

Page 28 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=28' data-page='28' class='cut-thumb lazyload' alt='Page 28: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/28.jpg' width='140' height='200' /> 28.

Page 29 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=29' data-page='29' class='cut-thumb lazyload' alt='Page 29: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/29.jpg' width='140' height='200' /> 29.

Page 30 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=30' data-page='30' class='cut-thumb lazyload' alt='Page 30: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/30.jpg' width='140' height='200' /> 30.

Page 31 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=31' data-page='31' class='cut-thumb lazyload' alt='Page 31: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/31.jpg' width='140' height='200' /> 31.

Page 32 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=32' data-page='32' class='cut-thumb lazyload' alt='Page 32: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/32.jpg' width='140' height='200' /> 32.

Page 33 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=33' data-page='33' class='cut-thumb lazyload' alt='Page 33: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/33.jpg' width='140' height='200' /> 33.

Page 34 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=34' data-page='34' class='cut-thumb lazyload' alt='Page 34: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/34.jpg' width='140' height='200' /> 34.

Page 35 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=35' data-page='35' class='cut-thumb lazyload' alt='Page 35: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/35.jpg' width='140' height='200' /> 35.

Page 36 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=36' data-page='36' class='cut-thumb lazyload' alt='Page 36: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/36.jpg' width='140' height='200' /> 36.

Page 37 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=37' data-page='37' class='cut-thumb lazyload' alt='Page 37: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/37.jpg' width='140' height='200' /> 37.

Page 38 <img data-url='document/-paying-the-piper-considerations-for-managing-high-cost-antidotes-ml-background.html?page=38' data-page='38' class='cut-thumb lazyload' alt='Page 38: nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader043.cupdf.com/reader043/viewer/2022022721/5c67217c09d3f230488d3fad/html5/thumbnails/38.jpg' width='140' height='200' /> 38.

nyschp.memberclicks.net · Paying the Piper: Considerations for managing high cost antidotes Ml Background Reasons Pharmacoeconomics Risks vs Benefitsm Jeanna M. Marraffa, Pharm.D.,

Documents